EAR - Eargo, Inc.
After hours:
| Previous close | 4.7600 |
| Open | 4.7700 |
| Bid | 4.7800 x 800 |
| Ask | 4.9500 x 800 |
| Day's range | 4.6200 - 4.9800 |
| 52-week range | 3.9200 - 68.8000 |
| Volume | |
| Avg. volume | 46,563 |
| Market cap | 101.013M |
| Beta (5Y monthly) | 1.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -24.4800 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireEargo Reports First Quarter 2023 Financial Results
Recent Highlights: Net revenues of $11.8 million in the first quarter of 2023, up 29% year-over-yearGross systems shipped of 8,705, up 51% year-over-yearGAAP total operating loss $22.8 million in the first quarter of 2023, compared to $30.4 million in the first quarter of 2022Commercially launched Eargo 7, a self-fitting hearing aid with the use of Sound Match via our mobile app, in February 2023Company expects modest sequential improvements to net operating cash burn in the remaining quarters o
- GlobeNewswire
Eargo to Report First Quarter 2023 Financial Results on May 11, 2023
SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the first quarter 2023 after market close on May 11, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (800)
- GlobeNewswire
Eargo Reports Fourth Quarter 2022 Financial Results
Recent Highlights: Net revenues of $12.9 million in the fourth quarter of 2022, compared to $10.1 million in the fourth quarter of 2021 and $7.9 million in the third quarter of 2022Gross systems shipped of 8,863, compared to 7,767 in the fourth quarter of 2021GAAP operating loss $23.9 million in the fourth quarter of 2022, compared to $45.2 million in the fourth quarter of 2021 and $26.0 million in the third quarter of 2022Cash and cash equivalents of $101.2 million as of December 31, 2022Prior
- GlobeNewswire
Eargo to Report Fourth Quarter 2022 Financial Results on March 23, 2023
SAN JOSE, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the fourth quarter 2022 after market close on March 23, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing
- GlobeNewswire
Nasdaq Confirms Eargo’s Minimum Bid Price Deficiency is Cured
SAN JOSE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (the “Company” or “Eargo”), a medical device company on a mission to improve the quality of life of people with hearing loss, announced today that it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) dated February 1, 2023 informing Eargo that the Company’s minimum bid price deficiency has been cured. The letter from Nasdaq follows the Company’s 1-for-20 reverse stock split approved by stockholders on Octob
- GlobeNewswire
Eargo Effects 1-for-20 Reverse Stock Split
SAN JOSE, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced that it has filed a Certificate of Amendment (the “Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the previously announced 1-for-20 reverse stock split of the Company’s common stock (the “Revers
- GlobeNewswire
Eargo to Complete a 1-for-20 Reverse Stock Split
SAN JOSE, Calif., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s common stock. The Company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on Wednesday, January 18, 2023, under the existing trading symbol “EAR”
- GlobeNewswire
Hearing Wellness Pioneer Eargo Launches Eargo 7, Its Most Revolutionary Device Yet, at CES
EARGO 7 OFFERS CLARITY MODE, CREATING ITS MOST NATURAL HEARING EXPERIENCE FOR THOSE WITH MILD TO MODERATE HEARING LOSS NEW OTC DEVICE TO BE AVAILABLE IN-STORE THROUGH PARTNERSHIP WITH VICTRA, ONE OF AMERICA’S LARGEST WIRELESS RETAILERSEARGO 5 AND 6 HAVE RECEIVED FDA 510(K) CLEARANCE AS SELF-FITTING HEARING AIDS; EARGO 7 WILL LAUNCH AS EARGO’S THIRD OVER-THE-COUNTER, SELF-FITTING DEVICEEARGO’S RECENT PARTNERSHIP WITH NATIONSBENEFITS CONTINUES TO ADVANCE ITS MISSION TO INCREASE ACCESS TO BETTER HE
Simply Wall St.Individual investors own 17% of Eargo, Inc. (NASDAQ:EAR) shares but private equity firms control 76% of the company
To get a sense of who is truly in control of Eargo, Inc. ( NASDAQ:EAR ), it is important to understand the ownership...
- GlobeNewswire
Eargo and NationsBenefits Announce Strategic Partnership
NationsBenefits to Sell Eargo Hearing Aids Over-The-Counter (OTC) beginning January 1, 2023SAN JOSE, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, and NationsBenefits, (a leading provider of supplemental benefits, flex cards, and member engagement solutions for health plans today announced a strategic partnership. The partnership will allow health plan members served by Natio
- GlobeNewswire
Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder
SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company’s rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company’s majority owner upon closing of the rights offering and conversion of Patient Square’s senior
- GlobeNewswire
Eargo, Inc. Welcomes Patient Square Capital As New Majority Owner Following Rights Offering
SAN JOSE, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (“Eargo” or “the Company”), a medical device company on a mission to improve the quality of life of people with hearing loss, is pleased to announce today that Patient Square Capital (“Patient Square”) has become the majority equity owner of the Company. Patient Square’s equity ownership of Eargo resulted from the conversion of Patient Square’s senior secured convertible notes per its previously announced investment in
- GlobeNewswire
Eargo Announces Closing of Rights Offering and Conversion of Patient Square Notes Into Shares of Eargo Common Stock
SAN JOSE, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (NASDAQ: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, announced today the closing and final results of its rights offering, which expired at 5:00 p.m. New York City time, on November 17, 2022. Pursuant to the terms of the rights offering, 57,745,050 shares of the Company’s common stock were purchased pursuant to the exercise of basic subscription
- GlobeNewswire
Important Reminder for Eargo Stockholders of Record as of October 24, 2022
DEADLINE TO PARTICIPATE IN EARGO RIGHTS OFFERING IS TOMORROW, NOVEMBER 17, 2022: FOR U.S. HOLDERS WHO HOLD SHARES THROUGH A BROKERAGE ACCOUNT: 2:15 P.M., NEW YORK CITY TIME, ON NOVEMBER 17, 2022, SUBJECT TO ANY OTHER DEADLINES SET BY YOUR BROKER FOR U.S. REGISTERED HOLDERS: 5:00 P.M., NEW YORK CITY TIME, ON NOVEMBER 17, 2022 Eargo stockholders should contact Morrow Sodali, Eargo’s information agent for the rights offering, for assistance in participating in the rights offering by calling (800) 6
- Simply Wall St.
Eargo Third Quarter 2022 Earnings: US$1.29 loss per share (vs US$2.02 loss in 3Q 2021)
Eargo ( NASDAQ:EAR ) Third Quarter 2022 Results Key Financial Results Net loss: US$50.6m (loss narrowed by 36% from 3Q...
- GlobeNewswire
Eargo Announces Issuance of Quarterly Report for Third Fiscal Quarter
SAN JOSE, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (NASDAQ: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the filing of Eargo’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 (the “Form 10-Q”). On October 31, 2022, Eargo announced the launch of a rights offering of an aggregate of 375,000,000 shares of common stock at a subscription price of $0.50 pe
GlobeNewswireEargo Now Available for Purchase in ~1,500 Victra Wireless Stores Nationwide
Eargo Announces Partnership with Victra, one of America’s Largest Wireless Retailers, for In-Person Retail Experience Across the Country In-store Display In-store Display SAN JOSE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the availability of Eargo in approximately 1,500 Victra Wireless stores across the country through a partnership between the companies.
- GlobeNewswire
Eargo Reports Third Quarter 2022 Financial Results
Third Quarter 2022 Highlights: Net revenues of $7.9 million, compared to ($22.9) million in the prior year periodGross systems shipped of 5,156, compared to 13,117 in the prior year periodReturn accrual rate of 32.3%, compared to 46.4% in the prior year periodGAAP gross margin of 24.0%; non-GAAP gross margin of 24.5%GAAP sales and marketing expense as a percent of net revenues of 142.7%; non-GAAP sales and marketing expense as a percent of net revenues of 134.5%Cash and cash equivalents of $88.1
- GlobeNewswire
Eargo Announces Commencement of Rights Offering
SAN JOSE, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (NASDAQ: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced that it has commenced a rights offering for up to 375 million newly issued shares of its common stock (the “Rights Offering”) and that it has launched its rights offering website. Stockholders of record at the close of business on October 24, 2022 will be receiving a final prosp
- GlobeNewswire
Eargo to Report Third Quarter 2022 Financial Results on November 3, 2022
SAN JOSE, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the third quarter 2022 after market close on November 3, 2022. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing
- GlobeNewswire
Eargo Announces Record Date for Proposed Rights Offering
Record Date established as October 24, 2022To be a stockholder of record, investors are advised to own EAR stock by 4:00 p.m. Eastern Time on Thursday, October 20, 2022 to account for T (trade) +2 settlement timing SAN JOSE, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (NASDAQ: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced that the record date for its proposed rights offering is October
- GlobeNewswire
Eargo to Hold Investor Update Conference Call on October 4, 2022
Company to Discuss Recently Commenced Proxy Solicitation Campaign for the 2022 Annual Meeting of Stockholders and the Importance of Voting as Soon as PossibleConference Call to be held on Tuesday, October 4, 2022 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time)VOTE now to ensure the Company can conduct its proposed rights offering and repay or convert the convertible notes held by Patient Square Capital SAN JOSE, Calif., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”)
- Simply Wall St.
Eargo (NASDAQ:EAR) dips 13% this week as increasing losses might not be inspiring confidence among its investors
Eargo, Inc. ( NASDAQ:EAR ) shareholders will doubtless be very grateful to see the share price up 33% in the last...
- GlobeNewswire
Eargo Announces Proxy Solicitation for 2022 Annual Meeting; Launch of Proxy Solicitation Web Site
SAN JOSE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ: EAR) (“Eargo”, the “Company,” “we,” or “us”), a medical device company on a mission to improve hearing health, today announced that it had begun its proxy solicitation for the 2022 Annual Meeting of the Stockholders to be held on Wednesday, October 12, 2022 at 11 A.M. Pacific Time (the “Annual Meeting”). The Company filed its definitive proxy Statement (as amended, the “Definitive Proxy Statement”) for the Annual Meeting o
- GlobeNewswire
Eargo Supports Over-the-Counter Hearing Aid Final Ruling
Company Applauds FDA for Increased Access, InnovationSAN JOSE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (“Eargo” or the “Company”), a medical device company on a mission to improve hearing health, announced its support of the new regulatory category of over-the-counter (“OTC”) hearing aids, as finalized by the Food and Drug Administration (the “FDA”) Wednesday, August 17, 2022. Christian Gormsen, President and Chief Executive Officer, said, “This ruling directly aligns